PhD Scientific Days 2020

Pathology and Oncology III. Lectures

Examination of Interleukin 1A and 1B Polimorphism in Medication-Related Osteonecrosis of the Jaw

Előadó neve

Dr. Szentpéteri, Szófia

Előadó munkahelye

Semmelweis University Department of Oro-Maxillofacial Surgery and Stomatology

Előadó telefonszáma

+36305167386

Előadó e-mail címe

szentpeteriszofia@gmail.com

Az előadás címe

Examination of Interleukin 1A and 1B Polimorphism in Medication-Related Osteonecrosis of the Jaw

Szerző(k) neve és munkahelye

Szófia Szentpéteri1, Zsolt Németh2, Mihály Vaszilkó3
1 Semmelweis University, Department of Oro-Maxillofacial Surgery and Stomatology
2 Semmelweis University, Department of Oro-Maxillofacial Surgery and Stomatology
3 Semmelweis University, Department of Oro-Maxillofacial Surgery and Stomatology

Szekció

Pathology and Oncology III. Lectures

Language of the presentation

Hungarian

Section, first choice

Pathology and Oncology

Section, second choice

Clinical Medicine

Összefoglaló szövege

Introduction: The medication-related osteonecrosis of the jaw (MRONJ) is the side effect of antiresorptive and antiangiogenic therapy, that used in treatment of oncologic disease and osteoporosis. The prognosis of the disease is very unfavorable.
Aims: We examine the single nucleotid polimorphism of interleukin 1A and 1B in development and prognosis of MRONJ. .
Methods: In our study we apply DentiGen Parodontitis Test for collecting samples. This test is suitable for sampling oral mucosa cells to ascertain interleukin 1A and 1B single nucleotid polymorphism (IL-1A-889, IL-1B+3953). The genetic samples were evaluated in the Istenhegyi Genediagnostic Center with DNA-hybridization technic.
In our investigation we made examination in patient group and control group. The role of gene polymorphism in development of the disease is examined by comparing the genetic results of patient group and control group. The investigation of gene polymorphism in the prognosis of the disease is based on treatment-induced stage improvement, recovery and the relapses following the treatment.
Results: During our investigation 150 genetic examination were performed. 91 patients were suffering from MRONJ and 59 patients were in the control group. In the patient group 51 (56,04%) patients carry unfavorable allelic variant, in the control group 22 (37,28%) patients had unfavorable allelic variant. We didn’t find any association (p=0,498) between the unfavorable polimorphism and the development of the MRONJ. In the patient group surgical therapy was used in 79 cases. In this group stage improvement was detected in 78 (98,73%) of the cases, recovery in 67 (88,15%) and relapses in 33 (49,25%). We didn’t find stage improvement in 1 (1,26%) case, recovery in 9 (11,8%) cases and relapses in 34 (50,74%) cases. 49 from 79 patients treated with surgical therapy had unfavorable allelic variant. We haven’t found any connection between the examined polymorphism and the stage improvement (p=0,382) or recovery (p=0,561). Significant association (p=0,022) was detected between the relapses and the carrying of unfavorable allelic variant.
Summery: We found significant association between relapses of MRONJ and the carrying of interleukin 1A and 1B polimorphism. Based on our study we didn’t find any association between interleukin 1 polimorphism and the development of MRONJ.

Additional Information

For me both languages (English and Hungarian) are appropiate for the presentation.

Bemutatás módja

Szóbeli

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

4726

Start

17:45

End

18:00

Authors (legacy)

Szófia Szentpéteri1, Zsolt Németh2, Mihály Vaszilkó3
1 Semmelweis University, Department of Oro-Maxillofacial Surgery and Stomatology
2 Semmelweis University, Department of Oro-Maxillofacial Surgery and Stomatology
3 Semmelweis University, Department of Oro-Maxillofacial Surgery and Stomatology